Holen Sie sich die Stockscreener-App
2.08
0.24%
-0.00
Schlusskurs vom Vortag:
$2.08
Offen:
$2.12
24-Stunden-Volumen:
108.81K
Relative Volume:
0.19
Marktkapitalisierung:
$89.12M
Einnahmen:
$88.55M
Nettoeinkommen (Verlust:
$-53.21M
KGV:
-1.6075
EPS:
-1.2939
Netto-Cashflow:
$-29.48M
1W Leistung:
-8.99%
1M Leistung:
+1.72%
6M Leistung:
+14.01%
1J Leistung:
+22.78%
1-Tages-Spanne:
$2.04
$2.16
1-Wochen-Bereich:
$2.04
$2.33
52-Wochen-Spanne:
$1.13
$2.89
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
2.075 | 89.33M | 88.55M | -53.21M | -29.48M | -1.2939 |
ABT
Abbott Laboratories
|
106.29 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.60 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
274.80 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.45 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx Corp Officer Radhakrishnan Srikanth Sells 14,245 Shares at $2.26 Each (NASDAQ: LUNG) - kalkinemedia.com
Pulmonx CEO French Glendon E. III Disposes of 41,882 Shares at $2.26 Each - kalkinemedia.com
Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares By Investing.com - Investing.com South Africa
Pulmonx chief science officer sells $32,192 in stock By Investing.com - Investing.com Australia
Pulmonx general counsel David Lehman sells $32,393 in stock By Investing.com - Investing.com Nigeria
Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares - Investing.com
Pulmonx general counsel David Lehman sells $32,393 in stock - Investing.com
Pulmonx chief science officer sells $32,192 in stock - Investing.com
Insider at Pulmonx (LUNG) sells shares to cover taxes - Stock Titan
Pulmonx (LUNG) exec sells shares to cover RSU taxes - Stock Titan
Pulmonx (LUNG) general counsel sells shares to cover RSU taxes - Stock Titan
Pulmonx Shares Fall Following Recent Gains - Yahoo Finance
Why is Pulmonx stock sliding today? - Investing.com
Why is Pulmonx stock sliding today? By Investing.com - Investing.com Australia
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Pulmonx will take investor meetings in Boston and New York Sept. 9-10 - Stock Titan
Pulmonx Corp (NASDAQ: LUNG) Share Price, LUNG Stock News, LUNG Share Price & Updates - Kalkine
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year - MarketBeat
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing - Stock Titan
Pulmonx at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript - The Globe and Mail
Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary - TradingView
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40 - Sahm
LUNG Looks 82.5% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
Pulmonx Target of Unusually Large Options Trading (NASDAQ:LUNG) - MarketBeat
Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4% - Investing.com
Pulmonx earnings beat by $0.04, revenue topped estimates - Investing.com
Pulmonx's Aug. 11 Boston fireside chat will be webcast live - Stock Titan
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055 - TradingKey
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pulmonx Corp expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Pulmonx Reports Q1 2026 Earnings with Strategic Outlook - Intellectia AI
Pulmonx Market Sentiment - Benzinga España
Pulmonx Corp. Revenue Breakdown – MUN:4NI - TradingView
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulmonx Corp (LUNG) Cash Flow - TradingKey
TradingKey - TradingKey
LUNG|Pulmonx Corp|Price:2.305|Chg%:+0.265 - TradingKey
Pulmonx (LUNG) Projected to Release Earnings on Wednesday - MarketBeat
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results - Stock Titan
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz - Kalkine Media
Pulmonx Corp highlights lung device strategy as a specialized medtech player - ad-hoc-news.de
Price to sales forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG - TradingView
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF - TradingView
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulmonx Corp-Aktie (LUNG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Radhakrishnan Srikanth | Chief Science & Techn. Officer |
Sep 01 '26 |
Sale |
2.26 |
14,245 |
32,194 |
316,994 |
| Lehman David Aaron | General Counsel |
Sep 01 '26 |
Sale |
2.26 |
14,334 |
32,395 |
361,827 |
| Rose Geoffrey Beran | Chief Commercial Officer |
Sep 01 '26 |
Sale |
2.26 |
7,879 |
17,807 |
449,832 |
| Radhakrishnan Srikanth | Chief Science &Techn. Officer |
Jun 01 '26 |
Sale |
1.54 |
14,497 |
22,325 |
331,239 |
| Lehman David Aaron | GENERAL COUNSEL |
Jun 01 '26 |
Sale |
1.54 |
14,594 |
22,475 |
376,161 |
| Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER |
Jun 01 '26 |
Sale |
1.54 |
8,023 |
12,355 |
457,711 |
| French Glendon E. III | President and CEO |
Jun 01 '26 |
Sale |
1.54 |
42,638 |
65,663 |
1,191,673 |
| French Glendon E. III | President and CEO |
Jun 02 '26 |
Sale |
1.57 |
13,511 |
21,212 |
1,178,162 |
| Radhakrishnan Srikanth | Chief Science &Techn. Officer |
Mar 02 '26 |
Sale |
1.43 |
10,483 |
14,991 |
170,736 |
| French Glendon E. III | President and CEO |
Mar 02 '26 |
Sale |
1.43 |
67,813 |
96,973 |
1,409,511 |
0.72%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):